Last reviewed · How we verify
NCT02812888
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism
trial testing thionamide treatment for 3 months in Hyperthyroidism in 240 participants. Status unknown.
1 March 2017
Quick facts
| Lead sponsor | Hu Hao |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 240 |
| Start date | 1 July 2016 |
| Primary completion | 1 March 2017 |
| Estimated completion | 1 June 2017 |
| Sites | 1 location across China |
Drugs / interventions tested
- thionamide treatment for 3 months — full drug profile →
Conditions studied
- Hyperthyroidism — all drugs for Hyperthyroidism →
Sponsor
Hu Hao — full company profile →
Who can join
Adults 18 to 60, any sex, with Hyperthyroidism. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Serum betatrophin levels
Time frame: Change from baseline at 3 months
Sponsor's own description
Clustering of various metabolic parameters including abdominal obesity, hyperglycaemia, low high-density lipoprotein cholesterol, elevated triglycerides and hypertension have been used worldwide as metabolic syndrome to predict cardiometabolic risk. Thyroid dysfunction impacts on various levels of these components. Recent evidence from HepG2 cells indicates that betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, a secreted protein that regulates glucose, lipid metabolism, and energy homeostasis, is induced by T3. However, the role of betatrophin in hyperthyroid patients is unknown. The objective was to study serum betatrophin levels in hyperthyroid patients and the association of serum betatrophin levels with hyperthyroidism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT02812888
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperthyroidism
Currently open trials in the same condition.
- NCT07369063 — Impact of Vitamin D Therapy on Thyroid Function and Antibody Levels in Pediatric Graves' Disease · Phase 2 · recruiting
- NCT07048548 — Assessment of THL and Potential Risk of Hypothyroidism in Healthcare Workers Exposed to Low-dose Ionizing Radiation · active not recruiting
- NCT07472062 — Development of a Non-Invasive Prognostic Test for Graves Orbitopathy · NA · active not recruiting
- NCT06794203 — Hyperthyroidism as a Potential Predictive of Worse Outcome of Renal Graft · recruiting
- NCT00001159 — Natural History of Thyroid Function Disorders · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02812888 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hu Hao
- Last refreshed: 5 July 2016
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02812888.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing